Reduced number of intravenous infusions

  • The number of infusions has come down from 56 to 14 compared to eflornithine monotherapy.
  • With NECT the treatment is shortened to 10 days instead of 14. This makes NECT a treatment that is far more practical and more convenient for the patients.

     Administered during the daytime

  • The infusions are reduced to twice a day instead of four times – one every 6 hours. The treatment can be administered during daytime. The patient does not require night time treatment, which puts less pressure on medical staff. NECT is therefore a far more suitable treatment for the remote and resource-poor settings where HAT is being treated.

 

Comparison between kit eflornithine (DFMO) and kit NECT


   (Source WHO/MSF-Logistique)

   Volume and weight of treatment divided by half

  • To make the treatment more accessible, a treatment kit has been designed and is distributed by WHO, in collaboration with MSF Logistique. The kit, which consists of the medicines and all the materials needed for the proper administration of NECT, can contain 4 full treatments in an approx. 36 kg package as opposed to the current 2 full treatments per kit with eflornithine monotherapy.
  • The volume per treatment also has come down to 37.5 dm3 instead of 85 dm3. This is a tremendous advantage in terms of logistics, especially when it comes to transport to remote areas in places such as the DRC.